Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 6/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 6/20 | 0.40 |
| ▸ | MMP2 | P08253 | 6/20 | 0.39 |
| ▸ | MMP1 | P03956 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022054 | 0.87 | METAP2 (0.56) | METAP2METAP1MMP3MMP2MMP1 | |
| SCHEMBL14985000 | 0.83 | METAP2 (0.57) | METAP2METAP1NPC1RAB9ACTSS | |
| SCHEMBL21880739 | 0.81 | METAP2 (0.56) | METAP2METAP1MMP3MMP2MMP1 | |
| SCHEMBL7350315 | 0.77 | METAP2 (0.77) | METAP2METAP1NPC1RAB9A | |
| SCHEMBL12022072 | 0.77 | METAP2 (0.49) | METAP2METAP1MMP3MMP2MMP1 | |
| SCHEMBL22010038 | 0.77 | LTA4H (0.47) | METAP2METAP1 | |
| SCHEMBL19879425 | 0.76 | METAP2 (0.54) | METAP2METAP1MMP3MMP2MMP1 | |
| SCHEMBL17367862 | 0.76 | METAP2 (0.72) | METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL7362199 | 0.76 | METAP2 (0.76) | METAP2METAP1NPC1RAB9A | |
| SCHEMBL23119813 | 0.75 | ALDH1A1 (0.45) | METAP2METAP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | METAP2 1/4885METAP1 2/4885MMP3 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.